WO1997024116A3 - METHODS OF TREATMENT WITH COMPOUNDS HAVING RARα RECEPTOR SPECIFIC OR SELECTIVE ACTIVITY - Google Patents

METHODS OF TREATMENT WITH COMPOUNDS HAVING RARα RECEPTOR SPECIFIC OR SELECTIVE ACTIVITY Download PDF

Info

Publication number
WO1997024116A3
WO1997024116A3 PCT/US1996/020511 US9620511W WO9724116A3 WO 1997024116 A3 WO1997024116 A3 WO 1997024116A3 US 9620511 W US9620511 W US 9620511W WO 9724116 A3 WO9724116 A3 WO 9724116A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
compounds
methods
receptor specific
retinoids
Prior art date
Application number
PCT/US1996/020511
Other languages
French (fr)
Other versions
WO1997024116A2 (en
Inventor
Min Teng
Tien T Duong
Roshantha A Chandraratna
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Priority to JP09524502A priority Critical patent/JP2000502707A/en
Priority to EP96944978A priority patent/EP0869782A2/en
Priority to AU13450/97A priority patent/AU710483B2/en
Priority to HU0001643A priority patent/HUP0001643A3/en
Priority to BR9612318-4A priority patent/BR9612318A/en
Priority to NZ326155A priority patent/NZ326155A/en
Priority to KR1019980704939A priority patent/KR19990076814A/en
Priority to IL12512196A priority patent/IL125121A0/en
Publication of WO1997024116A2 publication Critical patent/WO1997024116A2/en
Publication of WO1997024116A3 publication Critical patent/WO1997024116A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N25/00—Investigating or analyzing materials by the use of thermal means
    • G01N25/20—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity
    • G01N25/48—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation
    • G01N25/4846—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation for a motionless, e.g. solid sample
    • G01N25/4866—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation for a motionless, e.g. solid sample by using a differential method

Abstract

Retinoid compounds which act specifically or selectively on RARα receptor subtypes in preference over RARβ and RARΗ receptor subtypes, possess desirable pharmaceutical properties associated with retinoids, and are particularly suitable for treatment of tumors, such as acute monocytic leukemia, cervical carcinoma, myeloma, ovarian carcinomas and head and neck carcinomas, without having one or more undesirable side effects of retinoids, such as inducement of weight loss, mucocutaneous toxicity, skin irritation and teratogenicity.
PCT/US1996/020511 1995-12-29 1996-12-16 METHODS OF TREATMENT WITH COMPOUNDS HAVING RARα RECEPTOR SPECIFIC OR SELECTIVE ACTIVITY WO1997024116A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP09524502A JP2000502707A (en) 1995-12-29 1996-12-16 Methods of treatment with compounds having RARα receptor specific or selective activity
EP96944978A EP0869782A2 (en) 1995-12-29 1996-12-16 METHODS OF TREATMENT WITH COMPOUNDS HAVING RAR $g(a)? RECEPTOR SPECIFIC OR SELECTIVE ACTIVITY
AU13450/97A AU710483B2 (en) 1995-12-29 1996-12-16 Methods of treatment with compounds having raralpha receptor specific or selective activity
HU0001643A HUP0001643A3 (en) 1995-12-29 1996-12-16 Use of chromane-, phenyl-, naphtyl- or pyridine carboxilic acid derivatives for preparing pharmaceutical compositions with antitumor activity
BR9612318-4A BR9612318A (en) 1995-12-29 1996-12-16 "methods of treatment with compounds having specific or selective activity on the raralpha receptor"
NZ326155A NZ326155A (en) 1995-12-29 1996-12-16 Use of compounds that bind selectively or specifically to RAR-alpha retinoid receptors for treating tumours
KR1019980704939A KR19990076814A (en) 1995-12-29 1996-12-16 Therapeutic methods using compounds having specific or selective activity of RAR alpha receptors
IL12512196A IL125121A0 (en) 1995-12-29 1996-12-16 Methods of treatment with compounds having raralpha receptor specific or selective activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/580,553 1995-12-29
US08/580,553 US5965606A (en) 1995-12-29 1995-12-29 Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity

Publications (2)

Publication Number Publication Date
WO1997024116A2 WO1997024116A2 (en) 1997-07-10
WO1997024116A3 true WO1997024116A3 (en) 1997-11-13

Family

ID=24321568

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/020511 WO1997024116A2 (en) 1995-12-29 1996-12-16 METHODS OF TREATMENT WITH COMPOUNDS HAVING RARα RECEPTOR SPECIFIC OR SELECTIVE ACTIVITY

Country Status (16)

Country Link
US (4) US5965606A (en)
EP (1) EP0869782A2 (en)
JP (1) JP2000502707A (en)
KR (1) KR19990076814A (en)
CN (1) CN1211180A (en)
AU (1) AU710483B2 (en)
BR (1) BR9612318A (en)
CA (1) CA2241758A1 (en)
CZ (1) CZ206998A3 (en)
HU (1) HUP0001643A3 (en)
IL (1) IL125121A0 (en)
MX (1) MX9805282A (en)
NZ (1) NZ326155A (en)
PL (1) PL327627A1 (en)
RU (1) RU2191009C2 (en)
WO (1) WO1997024116A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8198329B2 (en) 2004-03-10 2012-06-12 Research Foundation Itsuu Laboratory Memory consolidation promoting agent and method of use

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977125A (en) 1994-10-31 1999-11-02 Eisai Co., Ltd. Mono-or polyenic carboxylic acid derivatives
JP3964478B2 (en) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 Heterocycle-containing carboxylic acid derivative and pharmaceutical containing the same
US5965606A (en) * 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
US20040266715A1 (en) * 1999-03-31 2004-12-30 Wong Liang Fong Neurite regeneration
US20070213290A1 (en) * 1996-10-17 2007-09-13 Kingsman Alan J Neurite regeneration
GB9907461D0 (en) * 1999-03-31 1999-05-26 King S College London Neurite regeneration
WO1999020309A1 (en) * 1997-10-22 1999-04-29 Eisai Co., Ltd. Retinoic acid agonists as preventive and therapeutic agents for nephritis
US6083973A (en) * 1998-03-09 2000-07-04 Syntex (U.S.A.) Inc. Methods for inhibiting mucin secretion using RAR α selective antagonists
FR2776511B1 (en) * 1998-03-31 2001-05-11 Galderma Rech Dermatologique USE IN OR FOR THE PREPARATION OF A COMPOSITION OF AT LEAST ONE INHIBITOR OF RETINOIC ACID ACTIVITY
US6197798B1 (en) 1998-07-21 2001-03-06 Novartis Ag Amino-benzocycloalkane derivatives
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
JP3897594B2 (en) 2000-01-18 2007-03-28 ノバルティス アクチエンゲゼルシャフト Carboxamides useful as inhibitors of microsomal triglyceride transfer protein and apolipoprotein secretion
CA2399399A1 (en) * 2000-03-30 2001-10-11 Oxford Biomedica (Uk) Limited Retinoic acid receptor beta-2, its antagonists, and gene therapy vectors for the treatment of neurological disorders
TWI281911B (en) 2000-04-04 2007-06-01 Allergan Inc Treatment of tumors with RARalpha selective retinoid compounds in combination with other anti-tumor agents
US6369261B1 (en) 2000-08-29 2002-04-09 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6369225B1 (en) 2000-08-29 2002-04-09 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6380256B1 (en) * 2000-08-29 2002-04-30 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6313107B1 (en) 2000-08-29 2001-11-06 Allergan Sales, Inc. Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
ATE315558T1 (en) * 2000-08-29 2006-02-15 Allergan Inc COMPOUNDS WITH CYTOCHROME P450RA1 INHIBITIVE ACTIVITY
US6252090B1 (en) 2000-08-29 2001-06-26 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6387951B1 (en) 2000-08-29 2002-05-14 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
EP1935869A1 (en) * 2000-10-02 2008-06-25 F. Hoffmann-La Roche Ag Retinoids for the treatment of emphysema
EP1324970B1 (en) * 2000-10-02 2008-11-05 F. Hoffmann-La Roche Ag Retinoids for the treatment of emphysema
JP2002131257A (en) * 2000-10-26 2002-05-09 Nisshinbo Ind Inc Method and apparatus for measuring thermal conductivity, and method for fabricating heat insulating material
US6843595B2 (en) * 2001-01-26 2005-01-18 Waters Investment Limited Differential scanning calorimeter accounting for heat leakage
US7173134B2 (en) 2001-09-25 2007-02-06 Smithkline Beecham Corporation Selective RXR ligands
US6740676B2 (en) 2002-03-19 2004-05-25 Allergan, Inc. 4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-benzoic and 2-[4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-phenyl]-acetic acid, their esters and salts having cytochrome p450rai inhibitory activity
DE10227182B4 (en) * 2002-06-18 2013-01-31 Mettler-Toledo Ag Sample holder for differential thermal analysis
US6620963B1 (en) 2002-09-19 2003-09-16 Allergan, Inc. TRICYCLO[6.2.202,7]DODECA-2(7),3,5-TRIEN-4-CARBONYLAMINO-PHENYL AND TRICYCLO[6.2.202,7]DODECA-2(7),3,5-TRIEN-4-CARBONYLAMINO-HETEROARYL AND RELATED COMPOUNDS HAVING RARα RECEPTOR SELECTIVE BIOLOGICAL ACTIVITY
DE50308077D1 (en) * 2003-10-28 2007-10-11 Mettler Toledo Ag Thermoanalytical sensor and method for its production
US7077563B2 (en) * 2003-11-19 2006-07-18 General Electric Company Deposition sensor based on differential heat flux measurement
CA2545023A1 (en) 2003-11-25 2005-06-09 Novo Nordisk A/S Novel salicylic anilides
EP1717566A1 (en) * 2005-04-25 2006-11-02 Mettler-Toledo AG Thermoanalytical sensor
US20070060620A1 (en) * 2005-09-09 2007-03-15 John Sefton Use of RAR retinoid agonists to increase sperm count and sperm mobility in males
PL1937244T3 (en) 2005-09-30 2019-01-31 Io Therapeutics, Llc Treatment of cancer with specific rxr agonists
GB0605683D0 (en) * 2006-03-21 2006-05-03 Servomex Group Ltd Thermal conductivity sensor
US20080273572A1 (en) * 2006-06-02 2008-11-06 James Madison University Thermal detector for chemical or biological agents
JP4849961B2 (en) * 2006-06-05 2012-01-11 エスアイアイ・ナノテクノロジー株式会社 Thermal analyzer
US7470057B2 (en) * 2006-08-24 2008-12-30 Waters Investments Limited Differential scanning calorimeter sensor and method
JP2008089474A (en) * 2006-10-03 2008-04-17 Rigaku Corp Sensor unit for thermal analysis equipment and method for manufacturing the same
FR2925163B1 (en) * 2007-12-12 2010-02-26 Centre Nat Rech Scient METHOD AND APPARATUS FOR THERMAL ANALYSIS
EP2133690B1 (en) * 2008-06-13 2011-03-09 Mettler-Toledo AG Thermoanalytical instrument with dynamic power compensation
EP2214005B1 (en) 2009-02-03 2019-09-18 Mettler-Toledo GmbH Thermo-Analytical Instrument
US8517600B2 (en) * 2009-10-27 2013-08-27 General Electric Company Deposition sensor based on differential heat transfer resistance
JP5642525B2 (en) * 2010-02-02 2014-12-17 株式会社日立ハイテクサイエンス Differential scanning calorimeter
KR101853882B1 (en) * 2011-01-10 2018-05-02 삼성전자주식회사 Bio material test device and controlling method thereof
EP2685972A4 (en) * 2011-03-14 2014-08-13 Io Therapeutics Inc Inflammation and autoimmune disorder treatment using rar alpha selective agonists
JP6441073B2 (en) 2011-06-24 2018-12-19 ジーアールアイ バイオ, インコーポレイテッドGRI Bio, Inc. Prevention and treatment of inflammatory conditions
WO2013019653A1 (en) * 2011-07-29 2013-02-07 Tempero Pharmaceuticals, Inc. Compounds and methods
CN104114171A (en) 2011-12-13 2014-10-22 Io治疗公司 Autoimmune disorder treatment using RXR agonists
US10653650B2 (en) 2011-12-13 2020-05-19 Io Therapeutics, Inc. Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
MX365321B (en) * 2012-06-07 2019-05-29 Los Angeles Childrens Hospital Methods for treating neutropenia using retinoid agonists.
CN106413701A (en) 2014-02-18 2017-02-15 洛杉矶儿童医院 Compositions and methods for treating neutropenia
EP2921833B1 (en) * 2014-03-18 2016-12-28 Mettler-Toledo GmbH Thermoanalytical sensor and method for its production
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
DK3229811T3 (en) 2014-12-09 2021-03-08 Gri Bio Inc PREVENTION AND TREATMENT OF INFLAMMATIONAL DISEASES
WO2016144976A1 (en) * 2015-03-09 2016-09-15 Kings College London Combination therapy with rar alpha agonists for enhancing th1 response
BR112017020745A2 (en) 2015-03-31 2018-07-17 Syros Pharmaceuticals Inc patient stratification methods for treatment with retinoic acid α-receptor agonists.
CN113144203A (en) 2015-09-28 2021-07-23 阿祖拉眼科有限公司 Thiol and disulfide-containing agents for increasing meibomian gland lipid secretion
PL3368080T3 (en) 2015-10-31 2023-09-11 Io Therapeutics, Inc. Treatment of nervous system disorders using combinations of rxr agonists and thyroid hormones
ES2898676T3 (en) * 2015-11-25 2022-03-08 Io Therapeutics Inc Selective CYP26-resistant rar-alpha agonists in cancer treatment
MX2018010863A (en) 2016-03-10 2019-01-10 Io Therapeutics Inc Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones.
EP4166160A1 (en) 2016-03-10 2023-04-19 IO Therapeutics, Inc. Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones
US9868994B2 (en) 2016-04-08 2018-01-16 Syros Pharmaceuticals, Inc. Methods of stratifying patients for treatment with retinoic acid receptor-α agonists
MX2018012250A (en) 2016-04-08 2019-06-24 Syros Pharmaceuticals Inc Rara agonists for the treatment of aml and mds.
CA3019349A1 (en) 2016-04-14 2017-10-19 Azura Ophthalmics Ltd. Selenium disulfide compositions for use in treating meibomian gland dysfunction
CN108078966B (en) * 2016-11-22 2021-08-17 厦门大学 Use of aromatic nitroethylene compounds
EP3651764A4 (en) 2017-07-13 2021-09-22 IO Therapeutics, Inc. Immunomodulatory retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
EP3675843A4 (en) * 2017-08-31 2021-11-03 IO Therapeutics, Inc. Rar selective agonists in combination with immune modulators for cancer immunotherapy
MX2020003223A (en) 2017-09-20 2020-09-21 Io Therapeutics Inc Treatment of disease with esters of selective rxr agonists.
US11474054B2 (en) * 2018-10-22 2022-10-18 Equistar Chemicals, Lp Temperature control apparatuses and methods
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
WO2020263960A1 (en) * 2019-06-28 2020-12-30 Carl Wagner Compositions comprising a retinoid x receptor (rxr) agonist, a retinoic acid receptor (rar) agonist, or a dual rxr/rar agonist
EP4087655A4 (en) 2020-01-10 2024-02-21 Azura Ophthalmics Ltd Instructions for composition and sensitivity
WO2023108012A1 (en) 2021-12-07 2023-06-15 Io Therapeutics, Inc. Use of an rxr agonist and taxanes in treating her2+ cancers
US20230416190A1 (en) * 2022-06-27 2023-12-28 Io Therapeutics, Inc. Synthesis of tetrahydronaphthalenols and uses thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0170105A2 (en) * 1984-07-07 1986-02-05 Koichi Prof. Dr. Shudo Benzoic acid derivatives
EP0350846A2 (en) * 1988-07-14 1990-01-17 F. Hoffmann-La Roche Ag Condensed heterocyclic compounds and their use in therapy
EP0514269A1 (en) * 1991-05-15 1992-11-19 Centre International De Recherches Dermatologiques Galderma, ( Cird Galderma) Imino-derivatives, process for their preparation and their use in human and veterinary medicine and in cosmetics
WO1993003713A1 (en) * 1991-08-23 1993-03-04 The Salk Institute For Biological Studies Use of selective ligands for treatment of disease states responsive to steroid or steroid-like hormones
JPH0672866A (en) * 1992-07-02 1994-03-15 Chugoku Igakuka Gakuin Yakubutsu Kenkyusho Differentiation inducing agent
US5420145A (en) * 1993-03-22 1995-05-30 Koichi Shudo Carboxylic acid derivative
WO1996032101A1 (en) * 1995-04-10 1996-10-17 Taiho Pharmaceutical Co., Ltd. Cancerous metastasis inhibitor

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4067975A (en) * 1975-08-04 1978-01-10 Yu Ruey J Treatment of psoriasis with 6-aminonicotinamide and thionicotinamide
US4085091A (en) 1976-12-16 1978-04-18 E. I. Dupont De Nemours And Company Thermally stable, rigid polyesters from thermally stable, rigid dibasic acids and aromatic dihydroxy compounds
US4111717A (en) * 1977-06-29 1978-09-05 Leeds & Northrup Company Small-size high-performance radiation thermopile
US4326055A (en) 1977-12-22 1982-04-20 Hoffmann-La Roche Inc. Stilbene derivatives
FR2440353A1 (en) * 1978-11-03 1980-05-30 Science Union & Cie NOVEL ARYLETHANOLS, PROCESSES FOR OBTAINING THEM AND THEIR USE AS A MEDICINAL PRODUCT
EP0047817A3 (en) 1980-08-14 1982-05-26 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Hydrogenated naphthalines, their preparation and application, and mixtures containing such naphthalines
CH651034A5 (en) 1982-05-12 1985-08-30 Hoffmann La Roche CHROMAN, THIOCHROMAN OR 1,2,3,4-TETRAHYDROCHINOLIN DERIVATIVES AND THEIR USE AS MEDICINAL ACTIVE SUBSTANCES.
DK158947C (en) 1982-07-06 1991-01-21 Hoffmann La Roche TETRAHYDRONAPHTHALIN, BENZOFURAN AND BENZOTHIOPHENDER DERIVATIVES, PREPARATION AND USE THEREOF, AND RODENTICID CONTAINING SUCH DERIVATIVES
US4794188A (en) * 1982-12-01 1988-12-27 Usv Pharmaceutical Corporation Certain unsymmetrical quinolinyl ethers having anti-inflammatory and anti-allergic activity
ATE38835T1 (en) 1983-07-05 1988-12-15 Pfizer CARBONIC ACID DERIVATIVES USEFUL IN PREVENTING DECOMPOSITION OF CARTILAGE.
WO1985000806A1 (en) 1983-08-08 1985-02-28 Sri International Benzonorbornenyl, benzopyranyl and benzothiopyranyl retinoic acid analogues
FR2562539B1 (en) 1984-04-06 1987-04-17 Chauvin Blache Lab NOVEL VINYL-4 BENZOIC ACID DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC APPLICATIONS THEREOF AND AS LIGANDS
US4826984A (en) 1984-04-09 1989-05-02 The Board Of Regents For The Oklahoma Agricultural And Mechanical College Acting For And On Behalf Of Oklahoma State University Heteroarotinoid compounds as anticancer agents
JPS60222445A (en) 1984-04-19 1985-11-07 Yoshitomi Pharmaceut Ind Ltd Phthalic acid compound
JPS6122046A (en) 1984-07-07 1986-01-30 Koichi Shiyudo Stilbene derivative
LU85544A1 (en) 1984-09-19 1986-04-03 Cird AROMATIC HETEROCYCLIC DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION IN THE THERAPEUTIC AND COSMETIC FIELDS
DE3434946A1 (en) 1984-09-22 1986-04-03 Basf Ag, 6700 Ludwigshafen DIARYLACETYLENE, THEIR PRODUCTION AND USE
DE3434942A1 (en) 1984-09-22 1986-04-03 Basf Ag, 6700 Ludwigshafen TETRALINE DERIVATIVES, THEIR PRODUCTION AND USE
DE3434947A1 (en) 1984-09-22 1986-04-03 Basf Ag, 6700 Ludwigshafen ISOXAZOLIC CARBONIC ACID DERIVATIVES, THEIR PRODUCTION AND USE
HU194405B (en) * 1985-05-10 1988-01-28 Magyar Optikai Muevek Temperature control system for testing thermic phase transformations
DE3529489A1 (en) * 1985-08-16 1987-02-26 Max Planck Gesellschaft METHOD AND DEVICE FOR DETERMINING THE HEAT CAPACITY OF A SAMPLE
IL80270A0 (en) 1985-10-11 1987-01-30 Cird Naphthalene derivatives,their preparation and pharmaceutical compositions containing them
DE3602473A1 (en) 1986-01-28 1987-07-30 Basf Ag VINYLPHENOL DERIVATIVES, THEIR PRODUCTION AND USE
LU86351A1 (en) 1986-03-12 1987-11-11 Oreal BENZOPYRANNYL AND BENZOTHIOPYRANNYL BENZOIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE IN COSMETICS AND HUMAN AND VETERINARY MEDICINE
DE3615157A1 (en) 1986-05-05 1987-11-12 Schwabe Willmar Gmbh & Co 5-ARYLALKYL-4-ALKOXY-2 (5H) -FURANONE, INTERMEDIATE PRODUCTS AND METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS THERAPEUTIC ACTIVE SUBSTANCES
ZW6587A1 (en) 1986-05-13 1987-12-02 Hoffmann La Roche Tetrahydro naphthanline derivatives
ZW7487A1 (en) 1986-05-23 1987-12-16 Hoffmann La Roche Tetrahydronaphthaline and indane derivatives
ZW10287A1 (en) 1986-07-15 1988-01-13 Hoffmann La Roche Tetrahydronaphthaline and indane derivatives
US4739098A (en) 1986-09-22 1988-04-19 Allergan, Inc. Ethynylphenyl-containing retinoic acid derivatives
NZ222968A (en) 1986-12-24 1990-05-28 Allergan Inc Ethynylheteroaromatic derivatives and medicaments
US4927947A (en) 1986-12-24 1990-05-22 Allergan, Inc. Ethynylheteroaromatic-acids having retinoic acid-like activity
US5089509A (en) 1988-09-15 1992-02-18 Allergan, Inc. Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US5234926A (en) 1987-03-20 1993-08-10 Allergan, Inc. Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US5264578A (en) 1987-03-20 1993-11-23 Allergan, Inc. Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity
CA1305480C (en) 1987-03-20 1992-07-21 Roshantha A.S. Chandraratna Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US4810804A (en) 1987-03-26 1989-03-07 Allergan, Inc. Acetylenes disubstituted with a phenyl group and a heterobicyclic group having retinoid-like activity
ZA885192B (en) 1987-08-19 1989-04-26 Hoffmann La Roche Pharmaceutical preparations
CA1298309C (en) 1987-11-06 1992-03-31 Michael Klaus Benzocycloheptene derivatives
US5231113A (en) 1988-04-11 1993-07-27 Allergan, Inc. Tetralin esters of phenols or benzoic acids having retinoid like activity
AU618590B2 (en) 1988-04-11 1992-01-02 Allergan, Inc. Tetralin esters of phenols or benzoic acids having retinoid like activity
US4895868A (en) 1988-06-29 1990-01-23 Allergan, Inc. Thiochroman esters of phenols and terephthallates having retinoid-like activity
US5015658A (en) 1988-06-29 1991-05-14 Allergan, Inc. Thiochroman esters of phenols and terephthallates having retinoid-like activity
US5068252A (en) 1989-07-26 1991-11-26 Allergan, Inc. Methods of using phenylethenyl compounds having retinoid-like activity
US4992468A (en) 1989-07-26 1991-02-12 Allergan, Inc. Phenylethenyl compounds having retinoid-like activity
US5045551A (en) 1989-09-19 1991-09-03 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US5183827A (en) 1989-09-19 1993-02-02 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US5248777A (en) 1989-09-19 1993-09-28 Allergan, Inc. Process and intermediates for preparing compounds having a disubstituted acetylene moiety and retinoic acid-like biological activity
US5399561A (en) 1989-09-19 1995-03-21 Allergan, Inc. Acetylenes disubstituted with a phenyl or heteroaryl group and a 2-oxochromanyl, 2-oxothiochromanyl or 2-oxo-1,2,3,4-tetrahydro-quinolinyl group having retinoid-like biological activity
US5162546A (en) 1989-09-19 1992-11-10 Allergan, Inc. Acetylenes disubstituted with a phenyl group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US5023341A (en) 1989-09-19 1991-06-11 Allergan, Inc. Compounds having a disubstituted acetylene moiety and retinoic acid-like biological activity
US5053523A (en) 1989-09-19 1991-10-01 Allergan, Inc. Ethynyl-chroman compounds
US5272156A (en) 1989-09-19 1993-12-21 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a 2-substituted 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US4980369A (en) 1989-09-19 1990-12-25 Allergan, Inc. Acetylenes disubstituted with a phenyl group and a 2-substituted chromanyl or thiochromanyl group having retinoid-like activity
US5175185A (en) 1989-12-29 1992-12-29 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a substituted phenyl group having retinoid like activity
US5013744B1 (en) 1989-12-29 1994-09-20 Allegran Inc Acetylenes disubstituted with a pyridinyl group and a substituted phenyl group having retinoid like activity
US5264456A (en) 1989-12-29 1993-11-23 Allergan, Inc. Acetylenes disubstituted with a furyl group and a substituted phenyl group having retinoid like activity
US5006550A (en) 1989-12-29 1991-04-09 Allergan, Inc. Chroman esters of phenols and benzoic acids having retinoid-like activity
US5202471A (en) 1990-02-06 1993-04-13 Allergan, Inc. Alkyl, alkoxy and thioalkoxy substituted diphenyl acetylenes having retinoid like activity
WO1991016051A1 (en) 1990-04-16 1991-10-31 Rhône-Poulenc Rorer International (Holdings) Inc. Styryl-substituted monocyclic and bicyclic heteroaryl compounds which inhibit egf receptor tyrosine kinase
LU87821A1 (en) 1990-10-12 1992-05-25 Cird Galderma BI-AROMATIC COMPOUNDS, AND THEIR USE IN HUMAN AND VETERINARY MEDICINE AND IN COSMETICS
ES2094350T3 (en) 1991-02-13 1997-01-16 Allergan Inc CHROMAN AND THIOCROMANES WITH PHENYLETINYL SUBSTITUTES IN POSITION 7 THAT HAVE RETINOID-TYPE BIOLOGICAL ACTIVITY.
US5134159A (en) 1991-03-26 1992-07-28 Allergan, Inc. 7-chromanyl esters of phenols and benzoic acids having retinoid-like activity
WO1992017471A1 (en) 1991-03-26 1992-10-15 Allergan, Inc. Chromans and thiochromans with heteroarylethynyl substituents at the 7-position having retinoid-like biological activity
US5326898A (en) 1992-02-11 1994-07-05 Allergan, Inc. Substituted phenylethenyl compounds having retinoid-like biological activity
JP3499553B2 (en) 1992-02-11 2004-02-23 アラーガン、インコーポレイテッド Heteroaryl-substituted phenylethenyl compounds with retinoid-like biological activity
US5324840A (en) 1992-06-11 1994-06-28 Allergan, Inc. Method of treatment with compounds having retinoid-like activity and reduced skin toxicity and lacking teratogenic effects
US5288147A (en) * 1992-11-09 1994-02-22 Ta Instruments, Inc. Thermopile differential thermal analysis sensor
US5455265A (en) 1993-02-11 1995-10-03 Allergan, Inc. Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
US5399586A (en) 1993-03-11 1995-03-21 Allergan, Inc. Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity
EP0619116A3 (en) * 1993-04-05 1994-11-23 Hoechst Japan Use of synthetic retinoids for osteopathy.
US5344959A (en) 1993-05-18 1994-09-06 Allergan, Inc. Tetrahydronaphthyl and cyclopropyl substituted 1,3-butadienes having retinoid-like activity
US5475022A (en) 1993-10-18 1995-12-12 Allergan, Inc. Phenyl or heteroaryl and tetrahydronaphthyl substituted diene compounds having retinoid like biological activity
WO1995017889A1 (en) * 1993-12-29 1995-07-06 Kowa Tekuno Sachi Co., Ltd. Therapeutic composition for hyperparathyroidism of patient subjected to artificial dialysis
US5470999A (en) 1993-12-30 1995-11-28 Allergan, Inc. Cyclohexene and bicyclic aromatic substituted ethyne compounds having retinoid-like biological activity
US5451605A (en) 1993-12-30 1995-09-19 Allergan, Inc. 1,2-epoxycyclohexanyl and bicyclic aromatic substituted ethyne compounds having retinoid-like biological activity
US5426118A (en) 1993-12-30 1995-06-20 Allergan, Inc. [4-(1,2-epoxycyclohexanyl)but-3-en-1-ynyl]aromatic and heteroaromatic acids and derivatives having retinoid-like biological activity
CA2138000A1 (en) 1994-01-03 1995-07-04 John E. Starrett, Jr. Retinoid-like compounds
US5498755A (en) 1994-08-23 1996-03-12 Chandraratna; Roshantha A. Disubstituted aryl and heteroaryl imines having retinoid-like biological activity
US5489584A (en) 1994-12-29 1996-02-06 Allergan, Inc. Acetylenes disubstituted with a 5-amino or substituted 5-amino substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
US5498795A (en) 1994-12-29 1996-03-12 Allergan, Inc. Acetylenes disubstituted with hydroxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
FR2733564B1 (en) * 1995-04-27 1997-06-20 Peugeot DAMPING ARRANGEMENT BY ROLLING A FLUID AND SUSPENSION SYSTEM, ESPECIALLY A MOTOR VEHICLE, EQUIPPED WITH SUCH A DAMPING ARRANGEMENT
US5779363A (en) * 1995-09-27 1998-07-14 The Johns Hopkins University Capillary calorimetric cell and method of manufacturing same
US5965606A (en) * 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
US5813763A (en) * 1996-10-11 1998-09-29 Microcal Incorporated Ultrasensitive differential microcalorimeter
WO1998020314A2 (en) * 1996-11-01 1998-05-14 Ta Instruments, Inc. Differential scanning calorimeter
US6079873A (en) * 1997-10-20 2000-06-27 The United States Of America As Represented By The Secretary Of Commerce Micron-scale differential scanning calorimeter on a chip
JPH11160226A (en) * 1997-12-01 1999-06-18 Mitsubishi Chemical Corp Manufacturing method for corrosion sensor
JP3137605B2 (en) * 1998-07-14 2001-02-26 セイコーインスツルメンツ株式会社 Heat flux type differential scanning calorimeter

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0170105A2 (en) * 1984-07-07 1986-02-05 Koichi Prof. Dr. Shudo Benzoic acid derivatives
EP0350846A2 (en) * 1988-07-14 1990-01-17 F. Hoffmann-La Roche Ag Condensed heterocyclic compounds and their use in therapy
EP0514269A1 (en) * 1991-05-15 1992-11-19 Centre International De Recherches Dermatologiques Galderma, ( Cird Galderma) Imino-derivatives, process for their preparation and their use in human and veterinary medicine and in cosmetics
WO1993003713A1 (en) * 1991-08-23 1993-03-04 The Salk Institute For Biological Studies Use of selective ligands for treatment of disease states responsive to steroid or steroid-like hormones
JPH0672866A (en) * 1992-07-02 1994-03-15 Chugoku Igakuka Gakuin Yakubutsu Kenkyusho Differentiation inducing agent
US5420145A (en) * 1993-03-22 1995-05-30 Koichi Shudo Carboxylic acid derivative
WO1996032101A1 (en) * 1995-04-10 1996-10-17 Taiho Pharmaceutical Co., Ltd. Cancerous metastasis inhibitor

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 121, no. 9, 1994, Columbus, Ohio, US; abstract no. 108128d, XP002030814 *
DATABASE WPI Section Ch Week 9416, Derwent World Patents Index; Class B05, AN 94-128759, XP002030803 *
KAGECHIKA H ET AL: "RETINOBENZOIC ACIDS STRUCTURE-ACTIVITY RELATIONSHIPS OF AROMATIC AMIDES WITH RETINOIDAL ACTIVITY", JOURNAL OF MEDICINAL CHEMISTRY, vol. 31, no. 11, November 1988 (1988-11-01), pages 2182 - 2192, XP000608417 *
MIN TENG ET AL: "Identification of a Retinoic Acid Receptor alpha Subtype Specific Agonist", J. MED. CHEM., vol. 39, no. 16, 2 August 1996 (1996-08-02), pages 3035 - 3038, XP000652115 *
YU, BAOXIN ET AL: "Synthesis of p-substituted benzoylaminobenzoic acid (methyl esters) and its differentiation induction activities of human promyelocytic leukemia cells HL-60", HUAXI YIKE DAXUE XUEBAO, vol. 25, no. 1, 1994, pages 30 - 34 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8198329B2 (en) 2004-03-10 2012-06-12 Research Foundation Itsuu Laboratory Memory consolidation promoting agent and method of use
US8431613B2 (en) 2004-03-10 2013-04-30 Research Foundation Itsuu Laboratory Memory fixation accelerator

Also Published As

Publication number Publication date
US6610744B2 (en) 2003-08-26
BR9612318A (en) 1999-12-28
RU2191009C2 (en) 2002-10-20
CZ206998A3 (en) 1999-04-14
US20020077360A1 (en) 2002-06-20
HUP0001643A3 (en) 2003-01-28
US20020085615A1 (en) 2002-07-04
AU710483B2 (en) 1999-09-23
PL327627A1 (en) 1998-12-21
JP2000502707A (en) 2000-03-07
MX9805282A (en) 1998-10-31
US5965606A (en) 1999-10-12
KR19990076814A (en) 1999-10-15
CA2241758A1 (en) 1997-07-10
EP0869782A2 (en) 1998-10-14
IL125121A0 (en) 1999-01-26
US6508585B2 (en) 2003-01-21
HUP0001643A2 (en) 2001-05-28
AU1345097A (en) 1997-07-28
WO1997024116A2 (en) 1997-07-10
US6534544B1 (en) 2003-03-18
NZ326155A (en) 2000-08-25
CN1211180A (en) 1999-03-17

Similar Documents

Publication Publication Date Title
WO1997024116A3 (en) METHODS OF TREATMENT WITH COMPOUNDS HAVING RARα RECEPTOR SPECIFIC OR SELECTIVE ACTIVITY
NO2005009I2 (en) Emselex-darifenacin. Iupac name: (S) -2-α1-α2- (2,3-dihydrobenzofuran-5-yl) ethylÜ-3-pyrrolidinylü-2,2-diphenylacetamide
AU1208197A (en) Novel n-(substituted or unsubstituted)-4-substituted-6- (substituted or unsubstituted) phenoxy-2-pyridine carboxamide or thiocarboxamide, process for producing the same and herbicide using the same
BR9610838A (en) Process for treating an individual having a pathological condition involving neovascularization.
NO965084D0 (en) N- [3- (3-cyanopyrazolo [1,5-aÅpyrimidin-7-yl) fenylÅ -N-ethyl-acetamide
MX9600754A (en) An animal ear tag and method of application.
IT1280812B1 (en) MAGNETOTHERAPY APPARATUS.
AU1894295A (en) 2-cyano-1,3-dione derivatives useful as herbicides
PT751764E (en) RETINAL COMPOSITION
ES1023162Y (en) TREATMENT APPARATUS, IN PARTICULAR FOR FACIAL COSMETIC TREATMENT.
ES1023163Y (en) TREATMENT APPARATUS, IN PARTICULAR FOR FACIAL COSMETIC TREATMENT.
ZA964198B (en) Treatment regime for skin.
EP1018336A4 (en) Carcinostatics
BR9606955A (en) Substituted heterocycloalkenes
ATE320263T1 (en) USE OF HUMAN PROTEIN C FOR PRODUCING A MEDICINAL PRODUCT FOR TREATING HEPARIN-INDUCED THROMBOCYTOPENIA
ES1037597Y (en) DEVICE FOR SEWING DECORATIVELY DIFFERENT CLASSES OF ARTICLES, ESPECIALLY ARTICLES MANUFACTURED OF LEATHER.
FR2748919B1 (en) ADJUSTABLE ARMCHAIR, PARTICULARLY FOR GIVING BOTTLE
PL343079A1 (en) Biotin-binding receptor molecules
AU7227296A (en) 2-cyano-1,3-dione derivatives and herbicides containing the same as active ingredient
FR2687978B1 (en) BALANCING DEVICE FOR SHIPS, PARTICULARLY IN ROLLS.
UA42749C2 (en) Dimaleate salt of n, n-diethyl-8, 8-dipropyl-2-azaspiro[4.5] decane-2-propanamine, pharmaceutical composition, treatment method
ES1024176Y (en) PERFECTED APPARATUS FOR SKIN TREATMENT FOR AESTHETIC PURPOSES.
EP0820449A4 (en) Paclitaxel analogs, preparation and use as antitumor agents
RU94011030A (en) Method of increase of protective action time of lung- automatic breathing apparatuses
ES1032813Y (en) ICE CREAM WAFLE HOLDER, PERFECTED.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96180109.3

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI

ENP Entry into the national phase

Ref document number: 2241758

Country of ref document: CA

Ref document number: 2241758

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1019980704939

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PV1998-2069

Country of ref document: CZ

Ref document number: 98-01121

Country of ref document: RO

Ref document number: PA/A/1998/005282

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 326155

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1996944978

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996944978

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV1998-2069

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1019980704939

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: 1019980704939

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV1998-2069

Country of ref document: CZ